Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Nine analysts give Telix a consensus rating of "Moderate Buy" (1 sell, 1 hold, 6 buy, 1 strong buy) with an average 1‑year price objective of about $21.13.
• Recent results missed expectations: Telix reported ($0.01) EPS vs $0.05 expected and revenue of $206.72M vs $421.5M expected, and its shares opened at $9.13—well below the 12‑month high of $20 and above the 12‑month low of $6.28.
• Several hedge funds (including Portland Investment Counsel, Quadrature, Russell Investments and Millennium Management) have recently initiated or increased positions, signaling rising institutional interest in the stock.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $21.1250.

TLX has been the topic of a number of analyst reports. Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, January 19th. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Citigroup upped their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a "buy" rating in a research report on Tuesday, February 24th. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, Wall Street Zen cut Telix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, March 15th.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $9.13 on Monday. The firm has a 50-day moving average price of $7.71 and a two-hundred day moving average price of $8.72. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last announced its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. On average, equities analysts predict that Telix Pharmaceuticals will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Portland Investment Counsel Inc. acquired a new stake in shares of Telix Pharmaceuticals during the 3rd quarter worth approximately $1,225,000. Quadrature Capital Ltd bought a new position in Telix Pharmaceuticals in the fourth quarter valued at approximately $276,000. Russell Investments Group Ltd. acquired a new position in Telix Pharmaceuticals during the second quarter valued at approximately $975,000. Rhumbline Advisers raised its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in Telix Pharmaceuticals during the third quarter valued at approximately $1,883,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.